Article ISI
LANCET  (2022)

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Halperin, Scott A.; Ye, Lingyun; MacKinnon-Cameron, Donna; Smith, Bruce; Ikram, Aamer; Lanas, Fernando; Lourdes Guerrero, M.; Munoz Navarro, Sergio Raul; Sued, Omar; Lioznov, Dmitry A.; Dzutseva, Vitalina; Parveen, Ghazala; Zhu, Fengcai; Leppan, Laura; Langley, Joanne M.; et. al.

Abstract

Background The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies. In this study, we report results on the final efficacy and interim safety analyses of the phase 3 trial.

Más información

Título según WOS: Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Título de la Revista: LANCET
Volumen: 399
Número: 10321
Editorial: Elsevier Science Inc.
Fecha de publicación: 2022
Página de inicio: 237
Página final: 248
DOI:

10.1016/S0140-6736(21)02753-7
Notas: ISI